Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2016-10-27
Target enrollment:
Participant gender:
Summary
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind
clinical trial followed by conversion of each arm to active nintedanib for an additional 6
months comparing the effect of nintedanib 150mg bis in die (BID twice daily) on the
progression of IPF measured by using High Resolution Computerized Tomography(HRCT), lung
function, functional component (6MWT), biomarkers, and PRO component (PROs) with continued
treatment and assessments for up to 18 months.